Stephen Davis - Apr 29, 2023 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Role
CEO, Director
Signature
/s/ Austin D. Kim, Attorney-in-Fact
Stock symbol
ACAD
Transactions as of
Apr 29, 2023
Transactions value $
-$165,331
Form type
4
Date filed
5/2/2023, 07:02 PM
Previous filing
Apr 7, 2023
Next filing
May 3, 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACAD Common Stock Options Exercise $0 +15.6K +15.55% $0.00 116K Apr 29, 2023 Direct
transaction ACAD Common Stock Sale -$165K -7.81K -6.72% $21.18 108K May 1, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACAD Restricted Stock Units Options Exercise $0 -15.6K -100% $0.00* 0 Apr 29, 2023 Common Stock 15.6K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.
F2 Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F3 The restricted stock units vest in four equal annual installments beginning April 29, 2020.